Skip to main content

Samsung Epis Holdings

Samsung Epis Holdings Co., Ltd., operating as Samsung Bioepis, is a South Korea-based biopharmaceutical enterprise focused on the development and commercialization of biosimilar therapeutics. The company engineers biosimilar formulations targeting immunology, oncology, ophthalmology, hematology, and endocrinology therapeutic fields. Principal revenue drivers consist of commercial sales of approved biosimilar drugs, milestone licensing payments from global marketing partners, and contract development income. Samsung Bioepis serves hospital systems, specialty clinics, retail pharmacies, and clinical healthcare providers across North America, Europe, and Asia-Pacific. The enterprise holds a leading international position as an established developer and manufacturer of complex biosimilars. Samsung Epis Holdings Co., Ltd. is headquartered in Incheon, South Korea, operating as a core biopharmaceutical subsidiary within the Samsung Group.

10 of the funds FundTelligence covers report a position in Samsung Epis Holdings.

Legal name
Samsung Epis Holdings Co Ltd
Sector
Health Care
Country
South Korea
Funds holding it
10

Funds holding Samsung Epis Holdings

Showing the 8 largest of 10 funds holding it.

Loading...